Exhibit 99




Contact:



        M.S. Koly                              Thomas Redington
        Chief Executive Officer                Redington, Inc
        Delcath Systems, Inc.                  203/222-7399
        203/323-8668                           212/926-1733
        www.delcath.com                        www.redingtoninc.com


                    DELCATH APPROVES STOCK REPURCHASE PROGRAM





     STAMFORD, CT OCT. 1 - Delcath Systems, Inc. (Nasdaq: DCTH) today announced
that its board of directors approved a stock repurchase program whereby the
company is authorized to repurchase a portion of its common stock.

     The board approved the repurchase by the company of up to 7 percent of its
outstanding common stock at such times, at such prices and on such other terms
as the president and chief executive officer approves. Under the board's
authorization, the company is not obligated to repurchase any shares. Certain of
the directors of the company have also indicated that they may purchase
additional shares for their own account. Any purchases the company or its
directors may make will depend on market conditions.

     Delcath's common stock is listed on the Nasdaq Small Cap Market and the
Boston Stock Exchange under the symbols DCTH and DCT, respectively.

     Delcath, a development-stage company, is in the business of developing and
marketing a proprietary drug delivery system capable of introducing, and
removing, high-dose chemotherapy agents to a diseased organ system while greatly
inhibiting their entry into the general circulatory system.

                                      # # #

     This release contains "forward-looking statements" based on current
expectations but involving known and unknown risks and uncertainties. Actual
results or achievements may be materially different from those expressed or
implied. Delcath plans and objectives are based on assumptions involving
judgments with respect to future economic, competitive and market conditions,
its ability to consummate, and the



timing of, acquisitions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are beyond its
control. Therefore, there can be no assurance than any forward-looking statement
will prove to be accurate.

10/1/02